CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ: CERS) announced today that the German Red Cross in the Baden-Württemberg–Hessen region (DRK Frankfurt) has agreed to collaborate in the development of the company’s INTERCEPT Blood System for red blood cells. Terms of the agreement call for the DRK Frankfurt to invest both expertise and personnel in support of commercial system design, commercial system validation, and activities directed toward German regulatory approval. In return, the agreement provides for DRK Frankfurt to receive royalties on potential sales of the INTERCEPT red blood cell system in Europe.
